Provided by Tiger Trade Technology Pte. Ltd.

Quest Diagnostics

234.93
-0.0900-0.04%
Volume:246.83K
Turnover:58.49M
Market Cap:25.93B
PE:24.95
High:239.07
Open:236.63
Low:234.69
Close:235.02
52wk High:247.19
52wk Low:171.18
Shares:110.37M
Float Shares:110.00M
Volume Ratio:0.85
T/O Rate:0.22%
Dividend:3.32
Dividend Rate:1.41%
EPS(TTM):9.42
EPS(LYR):8.75
ROE:14.60%
ROA:6.40%
PB:3.45
PE(LYR):26.85

Loading ...

Quest Diagnostics ups FY26 adjusted EPS view to $11.05-$11.25 from $10.63-$10.83

TIPRANKS
·
Jul 23

Quest Diagnostics Shares up 5.8% Premarket After Co Forecasts Annual Revenue, Profit Above Estimates

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Q2 FY26 Diluted EPS Rises 15% to 2.84; Revenue Increases 10.2% to 3.04 Billion

Reuters
·
Jul 23

Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate

Benzinga Earnings
·
Jul 23

Stock Track | Quest Diagnostics Soars 5.32% in Pre-market on Better-Than-Expected Q2 Revenue

Stock Track
·
Jul 23

Quest Diagnostics Outlook FY EPS USD 9.97-10.17

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Q2 Revenue USD 3,043 Million VS. Ibes Estimate USD 2,967 Million

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

THOMSON REUTERS
·
Jul 23

Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 23

Quest Diagnostics Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Jul 21

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Simply Wall St.
·
Jul 17

Quest Diagnostics Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 17

Buy Rating Reaffirmed on Quest Diagnostics as ACA-Related Risks Seen as Manageable and Earnings Resilient

TIPRANKS
·
Jul 16

Earning Preview: Quest Diagnostics Q2 revenue is expected to increase by 9.09%, and institutional views are bullish

Earnings Agent
·
Jul 16

Quest Diagnostics Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 16

Leerink Partners Adjusts Quest Diagnostics Price Target to $244 From $240, Maintains Outperform Rating

MT Newswires Live
·
Jul 16

Quest Diagnostics Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since June 2024

Dow Jones
·
Jul 15

Biovica Receives Ninth Work Order from Customer

Reuters
·
Jul 14

Quest Diagnostics is Maintained at Neutral by Baird

Dow Jones
·
Jul 13

Quest Diagnostics price target raised to $236 from $232 at Baird

TIPRANKS
·
Jul 13